Inhibrx Cash on Hand 2020-2022 | INBX

Inhibrx cash on hand from 2020 to 2022. Cash on hand can be defined as cash deposits at financial institutions that can immediately be withdrawn at any time, and investments maturing in one year or less that are highly liquid and therefore regarded as cash equivalents and reported with or near cash line items.
Inhibrx Annual Cash on Hand
(Millions of US $)
2021 $131
2020 $129
2019 $12
Inhibrx Quarterly Cash on Hand
(Millions of US $)
2022-03-31 $143
2021-12-31 $131
2021-09-30 $113
2021-06-30 $126
2021-03-31 $108
2020-12-31 $129
2020-09-30 $128
2020-06-30
2020-03-31
2019-12-31
2019-09-30
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.533B $0.007B
Inhibrx Inc. is a clinical-stage biotechnology company. The company's pipeline is focused on oncology and orphan diseases. Inhibrx Inc. is based in SAN DIEGO.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $162.107B 9.86
Bio-Rad Laboratories (BIO.B) United States $15.121B 32.79
QIAGEN (QGEN) Netherlands $10.761B 16.99
Biohaven Pharmaceutical Holding (BHVN) United States $10.111B 0.00
Ginkgo Bioworks Holdings (DNA) United States $5.648B 0.00
Emergent Biosolutions (EBS) United States $1.770B 7.57
Arcus Biosciences (RCUS) United States $1.376B 34.89
Myovant Sciences (MYOV) United Kingdom $1.033B 0.00
Zymeworks (ZYME) Canada $0.397B 0.00
Gelesis Holdings (GLS) United States $0.345B 0.00
Ambrx Biopharma (AMAM) United States $0.157B 0.00
Enzo Biochem (ENZ) United States $0.110B 22.60
SQZ Biotechnologies (SQZ) United States $0.100B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00